Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1984 Jul;74(1):1–6. doi: 10.1172/JCI111389

Natural anticoagulant mechanisms.

R D Rosenberg, J S Rosenberg
PMCID: PMC425178  PMID: 6330171

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki N., Moroi M., Sakata Y., Yoshida N., Matsuda M. Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest. 1978 May;61(5):1186–1195. doi: 10.1172/JCI109034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Björk I., Jackson C. M., Jörnvall H., Lavine K. K., Nordling K., Salsgiver W. J. The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin. J Biol Chem. 1982 Mar 10;257(5):2406–2411. [PubMed] [Google Scholar]
  3. Broekmans A. W., Veltkamp J. J., Bertina R. M. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med. 1983 Aug 11;309(6):340–344. doi: 10.1056/NEJM198308113090604. [DOI] [PubMed] [Google Scholar]
  4. Buonassisi V., Root M. Enzymatic degradation of heparin-related mucopolysaccharides from the surface of endothelial cell cultures. Biochim Biophys Acta. 1975 Mar 14;385(1):1–10. doi: 10.1016/0304-4165(75)90067-7. [DOI] [PubMed] [Google Scholar]
  5. Busch C., Owen W. G. Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest. 1982 Mar;69(3):726–729. doi: 10.1172/JCI110502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carrell N., Gabriel D. A., Blatt P. M., Carr M. E., McDonagh J. Hereditary dysfibrinogenemia in a patient with thrombotic disease. Blood. 1983 Aug;62(2):439–447. [PubMed] [Google Scholar]
  7. Comp P. C., Esmon C. T. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest. 1981 Nov;68(5):1221–1228. doi: 10.1172/JCI110368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Comp P. C., Jacocks R. M., Ferrell G. L., Esmon C. T. Activation of protein C in vivo. J Clin Invest. 1982 Jul;70(1):127–134. doi: 10.1172/JCI110584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dahlbäck B. Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. Biochem J. 1983 Mar 1;209(3):837–846. doi: 10.1042/bj2090837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dahlbäck B., Stenflo J. Inhibitory effect of activated protein C on activation of prothrombin by platelet-bound factor Xa. Eur J Biochem. 1980 Jun;107(2):331–335. doi: 10.1111/j.1432-1033.1980.tb06033.x. [DOI] [PubMed] [Google Scholar]
  11. Damus P. S., Hicks M., Rosenberg R. D. Anticoagulant action of heparin. Nature. 1973 Dec 7;246(5432):355–357. doi: 10.1038/246355a0. [DOI] [PubMed] [Google Scholar]
  12. EGEBERG O. INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA. Thromb Diath Haemorrh. 1965 Jun 15;13:516–530. [PubMed] [Google Scholar]
  13. Esmon C. T., Esmon N. L., Harris K. W. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982 Jul 25;257(14):7944–7947. [PubMed] [Google Scholar]
  14. Esmon C. T., Owen W. G. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2249–2252. doi: 10.1073/pnas.78.4.2249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Esmon N. L., Owen W. G., Esmon C. T. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1982 Jan 25;257(2):859–864. [PubMed] [Google Scholar]
  16. Fernlund P., Stenflo J. Amino acid sequence of the light chain of bovine protein C. J Biol Chem. 1982 Oct 25;257(20):12170–12179. [PubMed] [Google Scholar]
  17. Griffin J. H., Evatt B., Zimmerman T. S., Kleiss A. J., Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981 Nov;68(5):1370–1373. doi: 10.1172/JCI110385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gruenberg J. C., Smallridge R. C., Rosenberg R. D. Inherited antithrombin-III deficiency causing mesenteric venous infarction: a new clinical entity. Ann Surg. 1975 Jun;181(6):791–794. doi: 10.1097/00000658-197506000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Johansson L., Hedner U., Nilsson I. M. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand. 1978;203(6):477–480. doi: 10.1111/j.0954-6820.1978.tb14911.x. [DOI] [PubMed] [Google Scholar]
  20. Kazama M., Tahara C., Suzuki Z., Gohchi K., Abe T. Abnormal plasminogen, a case of recurrent thrombosis. 1981 Feb 15-Mar 1Thromb Res. 21(4-5):517–522. doi: 10.1016/0049-3848(81)90154-7. [DOI] [PubMed] [Google Scholar]
  21. Khoory M. S., Nesheim M. E., Bowie E. J., Mann K. G. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Invest. 1980 Mar;65(3):666–674. doi: 10.1172/JCI109712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kisiel W. Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. J Clin Invest. 1979 Sep;64(3):761–769. doi: 10.1172/JCI109521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Koide T., Odani S., Takahashi K., Ono T., Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci U S A. 1984 Jan;81(2):289–293. doi: 10.1073/pnas.81.2.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Levin E. G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804–6808. doi: 10.1073/pnas.80.22.6804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lindahl U., Bäckström G., Thunberg L., Leder I. G. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6551–6555. doi: 10.1073/pnas.77.11.6551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lollar P., Owen W. G. Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III. J Clin Invest. 1980 Dec;66(6):1222–1230. doi: 10.1172/JCI109973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Loskutoff D. J., Edgington T. E. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3903–3907. doi: 10.1073/pnas.74.9.3903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Loskutoff D. J. Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells. J Clin Invest. 1979 Jul;64(1):329–332. doi: 10.1172/JCI109457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Marciniak E., Farley C. H., DeSimone P. A. Familial thrombosis due to antithrombin 3 deficiency. Blood. 1974 Feb;43(2):219–231. [PubMed] [Google Scholar]
  30. Marcum J. A., Fritze L., Galli S. J., Karp G., Rosenberg R. D. Microvascular heparin-like species with anticoagulant activity. Am J Physiol. 1983 Nov;245(5 Pt 1):H725–H733. doi: 10.1152/ajpheart.1983.245.5.H725. [DOI] [PubMed] [Google Scholar]
  31. Marcum J. A., Rosenberg R. D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry. 1984 Apr 10;23(8):1730–1737. doi: 10.1021/bi00303a023. [DOI] [PubMed] [Google Scholar]
  32. Moroi M., Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem. 1976 Oct 10;251(19):5956–5965. [PubMed] [Google Scholar]
  33. Müllertz S., Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J. 1976 Dec 1;159(3):545–553. doi: 10.1042/bj1590545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Nesheim M. E., Canfield W. M., Kisiel W., Mann K. G. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem. 1982 Feb 10;257(3):1443–1447. [PubMed] [Google Scholar]
  35. Nossel H. L. Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis. Nature. 1981 May 14;291(5811):165–167. doi: 10.1038/291165a0. [DOI] [PubMed] [Google Scholar]
  36. Nossel H. L., Wasser J., Kaplan K. L., LaGamma K. S., Yudelman I., Canfield R. E. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline. J Clin Invest. 1979 Nov;64(5):1371–1378. doi: 10.1172/JCI109594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Oosta G. M., Gardner W. T., Beeler D. L., Rosenberg R. D. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A. 1981 Feb;78(2):829–833. doi: 10.1073/pnas.78.2.829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Owen J., Kvam D., Nossel H. L., Kaplan K. L., Kernoff P. B. Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. Blood. 1983 Mar;61(3):476–482. [PubMed] [Google Scholar]
  39. Owen W. G., Esmon C. T. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1981 Jun 10;256(11):5532–5535. [PubMed] [Google Scholar]
  40. Rijken D. C., Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981 Jul 10;256(13):7035–7041. [PubMed] [Google Scholar]
  41. Rosenberg J. S., McKenna P. W., Rosenberg R. D. Inhibition of human factor IXa by human antithrombin. J Biol Chem. 1975 Dec 10;250(23):8883–8888. [PubMed] [Google Scholar]
  42. Rosenberg R. D., Armand G., Lam L. Structure-function relationships of heparin species. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3065–3069. doi: 10.1073/pnas.75.7.3065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rosenberg R. D., Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973 Sep 25;248(18):6490–6505. [PubMed] [Google Scholar]
  44. Rosenberg R. D., Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1218–1222. doi: 10.1073/pnas.76.3.1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sakuragawa N., Takahashi K., Kondo S., Koide T. Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Thromb Res. 1983 Jul 15;31(2):305–317. doi: 10.1016/0049-3848(83)90333-x. [DOI] [PubMed] [Google Scholar]
  46. Salem H. H., Broze G. J., Miletich J. P., Majerus P. W. The light chain of factor Va contains the activity of factor Va that accelerates protein C activation by thrombin. J Biol Chem. 1983 Jul 25;258(14):8531–8534. [PubMed] [Google Scholar]
  47. Seligsohn U., Berger A., Abend M., Rubin L., Attias D., Zivelin A., Rapaport S. I. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984 Mar 1;310(9):559–562. doi: 10.1056/NEJM198403013100904. [DOI] [PubMed] [Google Scholar]
  48. Simionescu M., Simionescu N., Silbert J. E., Palade G. E. Differentiated microdomains on the luminal surface of the capillary endothelium. II. Partial characterization of their anionic sites. J Cell Biol. 1981 Sep;90(3):614–621. doi: 10.1083/jcb.90.3.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Stead N. W., Bauer K. A., Kinney T. R., Lewis J. G., Campbell E. E., Shifman M. A., Rosenberg R. D., Pizzo S. V. Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. Am J Med. 1983 Jan;74(1):33–39. doi: 10.1016/0002-9343(83)91115-4. [DOI] [PubMed] [Google Scholar]
  50. Stead N., Kaplan A. P., Rosenberg R. D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem. 1976 Nov 10;251(21):6481–6488. [PubMed] [Google Scholar]
  51. Stone A. L., Beeler D., Oosta G., Rosenberg R. D. Circular dichroism spectroscopy of heparin-antithrombin interactions. Proc Natl Acad Sci U S A. 1982 Dec;79(23):7190–7194. doi: 10.1073/pnas.79.23.7190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Suzuki K., Nishioka J., Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem. 1983 Jan 10;258(1):163–168. [PubMed] [Google Scholar]
  53. Takagi T., Doolittle R. F. Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: amino-terminal sequences of intermediate and terminal fragments. Biochemistry. 1975 Mar 11;14(5):940–946. doi: 10.1021/bi00676a010. [DOI] [PubMed] [Google Scholar]
  54. Teitel J. M., Rosenberg R. D. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest. 1983 May;71(5):1383–1391. doi: 10.1172/JCI110891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Vehar G. A., Davie E. W. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry. 1980 Feb 5;19(3):401–410. doi: 10.1021/bi00544a001. [DOI] [PubMed] [Google Scholar]
  56. Walker F. J. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem. 1981 Nov 10;256(21):11128–11131. [PubMed] [Google Scholar]
  57. Walker F. J., Sexton P. W., Esmon C. T. The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta. 1979 Dec 7;571(2):333–342. doi: 10.1016/0005-2744(79)90103-7. [DOI] [PubMed] [Google Scholar]
  58. Wun T. C., Schleuning W. D., Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem. 1982 Mar 25;257(6):3276–3283. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES